Navigation Links
Confirmation of HGT Business Day - 18th November 2008
Date:11/12/2008

LEXINGTON, Massachusetts, November 12 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is holding an update on its Human Genetic Therapies (HGT) business for analysts and investors on 18th November 2008.

The seminar will include both an overview of Shire's overall HGT strategy and an in-depth look at the portfolio of HGT products both on the market and in development. The session will start at 9.00am (ET) and will finish at 2.30pm (ET). It is being held at Shire's HGT offices in Lexington, Massachusetts and will be webcast at http://www.shire.com. The seminar will not be providing an update on current trading. Further information on the seminar will be available on the Company's website, http://www.shire.com.

Presentations will be made by Angus Russell, Shire's Chief Executive, Sylvie Gregoire, President of Shire HGT and her senior team. In addition, Shire is pleased to announce that Pr. Marco Cicardi, M.D. University of Milan and Specialist in Angioedema will present on Hereditary Angioedema.

Notes to editors

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on the Company's ADHD franchise; patents, including but not limited to, legal challenges relating to the Company's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); the Company's ability to secure new products for commercialization and/or development; the Company's proposed offer for Jerini AG, including but not limited to, the Company's ability to successfully complete the offer and integrate Jerini AG, as well as realize the anticipated benefits of the acquisition; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE Shire Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
2. Confirmation of Strong Growth Over the First Half of 2008
3. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
4. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
8. ThromboGenics N.V.: Business Update
9. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
10. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
11. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
Breaking Biology Technology:
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):